Purpose: The aims of this study were to describe symptoms attributed to endocrine therapy (ET) and perceptions of ET in a sample of young women with breast cancer and to explore whether these factors are associated with adherence to ET. Methods: An online questionnaire was completed by 106 young women taking ET for hormone receptorpositive breast cancer. In addition to demographic and medical characteristics, the survey assessed symptom attribution, emotions, and perceptions related to ET. A supplemental survey measuring adherence to ET was completed by 82/106 women. Means, medians, and frequency distributions were calculated for continuous and categorical covariates, respectively. An exploratory analysis evaluated whether adherence was associated with patient characteristics and views. Results: The mean age of respondents was 39 years (range 22-45 years). Two-thirds of women had stage 1 or 2 breast cancer. Women attributed an average of nine symptoms to ET; hot flashes, night sweats, and decreased libido were the most frequently attributed symptoms. Positive emotions toward ET were more common than negative emotions were, although only 48% of respondents believed that ET was essential. Women of higher financial status and those who reported more positive emotions toward ET reported greater adherence with ET. A significant difference in symptom attribution was not detected between less and more adherent respondents. Conclusions: Young women's views regarding ET may play an important role in determining adherence behavior. Given that young women have a higher risk of recurrence, some of which may be attributable to ET non-adherence, further work is needed to confirm these findings and determine whether interventions designed to modify young women's perceptions of ET could promote adherence.
F
ive years of adjuvant endocrine therapy (ET) with tamoxifen or an aromatase inhibitor reduces recurrence and improves survival in women with hormone receptor positive (HR+) breast cancer. 1 The ATLAS and aTTom trials recently demonstrated that 10 years of tamoxifen further reduces the risk of breast cancer recurrence and mortality compared to 5 years of treatment. 2, 3 Non-adherence to ET (i.e., failure to take ET as prescribed) has been associated with increased mortality, as has non-persistence (i.e., early discontinuation). [4] [5] [6] Despite the efficacy of ET, non-adherence is relatively common. A meta-regression analysis using data from 26 studies estimated non-adherence (e.g., using medication possession ratio [MPR] <80%) to range from 20% at 1 year to 32% at 5 years, although even higher rates of nonadherence have been reported. 7, 8 Adherence to ET may be critically important for young women given their increased risk of breast cancer recurrence and decreased survival. Young women are also less likely than older premenopausal women are to experience long-term ovarian dysfunction from chemotherapy alone, and are therefore less likely to benefit from this chemoendocrine effect. 9 In this context, it is concerning that young age is associated with non-adherence with ET. 5, 8, [10] [11] [12] [13] Hershmann et al. reported women younger than 40 years of age were 40% more likely to be non-adherent (i.e., MPR <80%) than those 50-65 years old ( p < 0.001). 11 Studies including breast cancer patients of all ages have reported several additional demographic and medical characteristics associated with higher ET adherence such as higher income and being married 10, 14, 15 ; conversely, non-white race and prior mastectomy have been identified as predictors of non-adherence. 10, 11 Importantly, patients' beliefs about their medications also predict adherence and may influence behavior to a greater extent than demographic and medical characteristics. 16 For example, adherence has been associated with perceived necessity of ET and views about long-term adverse effects of tamoxifen. 17, 18 Patient attribution of unpleasant symptoms to a medication is a common contributor to medication nonadherence. 19 In women being treated with ET, the number of symptoms attributed to the treatment seems to be a critical factor in predicting discontinuation, but few studies have examined which symptoms are attributed to ET. 18 This study examined young women's beliefs, perceptions, and attitudes regarding ET with the aim of identifying possible reasons for suboptimal ET adherence in this population. Specifically, the study focused on symptom attribution, beliefs about ET necessity, and emotions related to ET. As a secondary aim, the study explored whether the above factors differed between young women classified as either more or less adherent to ET. Better understanding of the factors that impact on young women's adherence to ET may suggest ways to improve outcomes in this population.
Methods

Study design
Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study (YWS) is an ongoing prospective cohort study examining biological, medical, and quality of life issues specific to women diagnosed with breast cancer at 40 years of age or younger. Study participants are mailed a baseline survey, followed by surveys twice a year for the initial 3 years following diagnosis and then annually. In October 2011, women who: (1) provided an email address upon study enrollment and (2) had hormone (estrogen and/or progesterone) receptor positivity ascertained by pathology or medical record review were emailed an invitation to complete a survey if they had taken ET in the prior year. Women currently taking ET were subsequently emailed supplemental questions in March 2012 regarding adherence to ET. The YWS is approved by the Institutional Review Board at the Dana-Farber/ Harvard Cancer Center and other participating sites.
Participants
Of 257 women invited to participate, 54 had not been on ET in the prior 12 months. Of the remaining 203 women, 113 responded and completed the survey (response rate: 56%). Seven of these 113 women had discontinued ET within the prior 12 months and were excluded from analyses because of their small number. A total of 82 women on ET completed the adherence supplement (Fig. 1 ).
Measures
The questionnaire was composed of measures used in a recent study of contributors to non-adherence that included more than 1400 women with an average age of 56 years. 15 Demographic and medical characteristics. Demographic characteristics included age, ethnicity, number of children, marital status, and educational background. Respondents were also asked to describe their household's financial situation. 20, 21 Clinical information including stage and treatment history was also self-reported. Specific survey items related to ET included type (tamoxifen or aromatase inhibitor) and duration of ET use.
Symptom attribution. Attribution of symptoms to ET was assessed using the Breast Cancer Prevention Trial Symptom Checklist. 22 Several symptoms (e.g., bone pain) were added to account for aromatase inhibitor side effects. Women were asked if they had been bothered by each of 47 symptoms in the past 4 weeks, and whether each symptom was attributed to ET. The total number of symptoms attributed to ET was calculated for each patient.
Perceptions of ET necessity and risk. Perceived necessity of ET was measured on a 0-10 scale with two items: (1) ''How much do you feel that your current ET can help reduce your risk of your breast cancer recurring?'' (0 = not at all, 10 = a great deal), and (2) ''How much do you feel that you need your current ET for your breast cancer?'' (0 = not at all, 10 = absolutely essential). 15, 16 Patients' understanding of their illness and treatment was assessed similarly (''How well do you feel you understand the current status of your diagnosis and treatment?'' 0 = not at all, 10 = very well). A single question addressed concern (0 = not at all concerned, 10 = extremely concerned) about the long-term adverse effects of ET. Perceived control over recurrence was assessed on a scale of 0 (no control) to 10 (extreme control).
Emotions toward ET. Emotions toward ET were evaluated using adapted items for affective properties of attitudes and included five positive (happy, calm, enthusiastic, comforted, accepting) and five negative (sad, annoyed, tense, reluctant, angry) emotions. 23 Participants indicated the degree to which each emotion described their feelings regarding ET (does not, slightly, definitely describes).
Concern about cancer recurrence. Fear of recurrence was evaluated with two questions: (1) ''Overall, how worried are you about your breast cancer recurring?'' (0 = not at all, 10 = extremely), and (2) ''How long do you think your breast cancer will continue to be in remission/cured?'' (0 = very short time, 10 = forever).
Adherence. Adherence to ET was assessed using an adaptation of the Morisky Medication Adherence scale, which has previously been used to evaluate adherence among breast cancer survivors. 15, 24 One question (''When you feel better, do you sometimes stop taking your medication?'') from the original Morisky Medication Adherence scale was not relevant to ET and so was removed and replaced with two items regarding intentional non-adherence: (1) ''I alter the dose of my current ET from what has been prescribed,'' and (2) ''I decide to miss a dose of my current ET.'' Responses for each item ranged from 1 (never) to 5 (always); scores from the five items were added to create a composite score ranging from 5 to 25, with a score of 5 considered ''most adherent.'' Patients were also asked how many doses of endocrine therapy they had missed in the past week and month.
Analysis
Means, medians, and frequency distributions were calculated for continuous and categorical outcomes, respectively. For items not answered by all participants, the number of respondents who answered the question is specified. Response scales for the items measuring perceived need for ET, long-term risk, and fear of recurrence (i.e., Likert scales that ranged from 0 to 10) were grouped as follows: ratings of 0-6 were categorized as low to moderate levels of endorsement, ratings of 7-9 were classified as high levels of endorsement, and a rating of 10 represented the highest level of endorsement. Positive and negative emotions were evaluated both categorically and continuously, with scores calculated by summing the endorsed items (each item scored as follows: 1 = does not describe; 2 = slightly describes; 3 = definitely describes). Pearson correlation coefficients were calculated to evaluate the relationship between positive/negative emotions and perceptions toward ET and breast cancer recurrence risk. 
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As a secondary analysis, differences in patient characteristics, perceptions, and attitudes toward ET were explored between women who were categorized as more adherent or less adherent using the modified Morisky scale. Respondents were dichotomized using the median cutoff (score of 6) on the Morisky scale; those scoring 5-6 were designated as more adherent (n = 46), and those scoring 7 or above were designated less adherent (n = 36). Additionally, symptom attribution (dichotomized as ''bothered by symptoms over the past 4 weeks and attributed to ET'' versus ''no symptoms'' or ''bothered by symptoms but not attributed to ET'') was compared between women taking tamoxifen and those taking an aromatase inhibitor. Two-tailed Fisher's exact test was used to compare proportional differences, and t-tests were used to compare means between more and less adherent women and between women on tamoxifen and aromatase inhibitors. All analyses were conducted in JMP Pro 10 and SAS v9.4.
Results
Demographic and medical characteristics
The mean age of participants was 38.5 years (range 22-45 years). Most participants were white and financially comfortable (Table 1) . At the time of the initial survey, 89% (93/ 105) were taking tamoxifen, and 11% (12/105) were taking an aromatase inhibitor. The average duration of ET use was 25 months (range 0.3-56 months).
Symptom attribution
On average, respondents (n = 104) attributed nine (range 0-28) symptoms experienced over the preceding month to ET. Hot flashes (75/104), night sweats (62/105), and decreased libido (55/104) were each attributed to ET by more than 50% of respondents. Nine other symptoms were attributed Perceptions and emotions toward ET and breast cancer recurrence Table 2 describes various perceptions and emotions related to ET. Overall, 48% of participants viewed ET as absolutely essential for the treatment of their breast cancer, and 36% believed they had a strong need for ET. Eighteen percent (19/105) believed ET could reduce their risk of recurrence by only a low to moderate amount; conversely, 56% (59/105) thought it would reduce the risk by a considerable amount, and 26% (27/105) thought it could greatly reduce their risk. Regarding fear of recurrence, 36% were considerably worried, and 23% endorsed extreme worry about recurrence. Forty percent (42/105) felt they had a very clear understanding of their illness and treatment. While 57% reported low to moderate levels of concern about long-term ET use, 43% reported either considerable or extreme concern. Thirty percent (31/103) believed their cancer would be in remission for only a short to moderate length of time.
More than 20% of women said the following emotions ''definitely describe'' their attitude toward ET: calm, comforted, and accepting. The most common negative emotion toward ET was annoyance, with 12% (12/99) and 42% (42/99) endorsing feeling ''definitely'' and ''slightly'' annoyed, respectively. Higher perceived recurrence risk reduction, less concern about long-term ET use, a better understanding of diagnosis and treatment, less worry about recurrence, and a greater belief the cancer would stay in remission or be cured were significantly ( p p 0.05) correlated to endorsement of positive emotions; negative emotions were significantly ( p p 0.05) correlated to lower perceived recurrence risk reduction, more concern about long-term ET use, and less understanding of diagnosis and treatment (Table 3) .
Adherence
Women reported relatively high rates of adherence to ET, with 84% (69/82) reporting no doses missed in the last week, and 59% (48/82) reporting no doses missed in the last month. Approximately one-quarter of respondents (20/82) indicated they had missed two or more doses of ET in the last month. Thirty-eight percent (31/82) had a Morisky scale score of 5 (a score of 5 indicates the highest level of adherence); the median Morisky score was 6 (range 5-13). Correlation of Morisky scale scores with self-reported doses missed over the past week and month were r = 0.40 and r = 0.58, respectively ( p < 0.0001).
An exploratory analysis was performed in which patients' perceptions, attributions, and emotions were stratified by adherence status (Table 2) . Compared with less adherent respondents, more adherent women were significantly more likely to report positive emotions toward ET, including happiness ( p = 0.009) and enthusiasm ( p = 0.05); more adherent women were less likely to report negative emotions such as annoyance ( p = 0.01) and reluctance ( p = 0.001). Of examined medical and sociodemographic characteristics, only financial status differed significantly between the more and less adherent group, with a greater percentage of more adherent women reporting they had enough money remaining for luxury purchases after paying bills (72% [31/43] 
Discussion
Young women are at increased risk of recurrence and death after a diagnosis of breast cancer compared with older women with breast cancer. While there are a number of reasons for this disparity, one likely contributor is that young women are less adherent and persistent with adjuvant ET. 4, 10, 11 Thus, understanding and optimizing adherence with ET in younger women may improve their outcomes. Due to their life stage at the time of diagnosis, younger women with breast cancer may experience various aspects of illness and therapy differently from older women. Patients' perceptions and emotions regarding ET are potentially modifiable, providing opportunities for future intervention. In support of the need to focus research on psychosocial factors, prior work has demonstrated that patients' beliefs about medications are powerful predictors of adherence and possibly more important than clinical and sociodemographic factors. 16 The present finding that more adherent women were more likely to report feeling happy and enthusiastic toward ET and less likely to report feeling annoyed or reluctant is consistent with prior research, and suggests that assessing women's self-reported emotions toward ET may help physicians to identify those at greatest risk for nonadherence. 15 Further, both positive and negative emotions were correlated to perceptions of risk reduction, concerns about long-term ET, and understanding of one's diagnosis and treatment, supporting these domains as potential targets for modification. 15 While side-effect burden has been repeatedly associated with non-adherence in older breast cancer patients, 8, 18, [25] [26] [27] a significant difference in symptom attribution was not detected between more and less adherent women. Of note, this survey did not measure symptom severity or how disruptive symptoms were in the context of women's lives, and less adherent women may experience more severe or disruptive symptoms. Further, more financially secure women may be more likely to pursue interventions to improve symptom burden, and such intervention was not evaluated in this analysis. Regardless, this study population experienced a substantial burden of symptoms. Importantly, on average, women attributed nine of their symptoms to ET. It has been suggested that younger women report more side effects from ET than older women do. 27 Menopausal symptoms may be more dramatic for young women. Prior work has shown an association between treatment-associated transition to menopause and worsened hot flash severity. 28 When examining reasons for non-adherence in young women on ET, continued attention to their experience of adverse effects is clearly warranted.
It is important to recognize that self-reported adherence, as assessed in this study, often overestimates more objective measures of adherence (e.g., as measured by medication possession ratios). 29, 30 The majority of respondents described themselves as adherent. However, 24.4% indicated they missed two or more doses in the last month. Importantly, even missing a few doses per month may place women at risk for future non-compliance and worse outcomes. Huiart et al. found that self-reported non-adherence (i.e., missing at least three pills in 10 months) was a significant risk factor for future tamoxifen discontinuation, 31 which in turn has implications for survival. [4] [5] [6] Despite the limitations of selfreported adherence, such metrics are valuable, as they can be used in clinical practice to identify patients in need of additional support.
While we did not find significant differences in beliefs endorsed by more and less adherent women, 52% of all respondents did not believe ET was essential, and 18% indicated ET would reduce their risk of recurrence by only a low to moderate amount. These findings highlight a need to educate young women with HR+ disease better about ET, especially given that greater perceived need for ET has been associated with improved adherence. 15, 17, 18 Forty-three percent of women also reported considerable or extreme concern about the long-term adverse effects of ET. Such concerns have been associated with increased risk of tamoxifen discontinuation. 17 The relatively high prevalence of concern among both more and less adherent women suggests value in emphasizing to patients that the potential benefits of ET usually far outweigh the risks of dangerous side effects. Of examined sociodemographic characteristics, only financial comfort level was significantly different between the more and less adherent groups. Other studies have similarly found an association between affluence and improved adherence. 10, 14, 15 There are several limitations to this study. The sample size was small, and response bias likely exists. Additionally, there are multiple variables potentially related to adherence behavior that were not examined in the present study, such as symptom severity, perceived social support, and concerns about fertility, which warrant further exploration.
This study provides important information regarding perceptions and attitudes related to ET and adherence behavior in a sample of young breast cancer survivors. Interventions designed to improve their perceptions and attitudes toward ET may represent an effective strategy for improving both ET adherence and associated morbidity and mortality outcomes in young women with breast cancer.
